Market Overview - As of November 5, U.S. stock index futures showed mixed results, with Dow futures up 0.04%, S&P 500 futures down 0.14%, and Nasdaq futures down 0.24% [1] - European indices also displayed varied performance, with Germany's DAX down 0.37%, UK's FTSE 100 up 0.04%, France's CAC40 down 0.05%, and the Euro Stoxx 50 down 0.41% [2][3] - WTI crude oil prices fell by 0.31% to $60.37 per barrel, while Brent crude oil dropped by 0.20% to $64.31 per barrel [3][4] Economic Indicators - The U.S. government shutdown has led to uncertainty regarding the release of key economic data, including the non-farm payroll report originally scheduled for release on Friday [5] - The ADP employment report, often referred to as the "little non-farm," is expected to show an increase of 28,000 jobs in October, a significant reversal from the previous month's loss of 32,000 jobs [5] Company Earnings and Forecasts - AMD reported a 36% year-over-year revenue increase to $9.25 billion, exceeding market expectations, but the outlook for Q4 revenue of $9.3 to $9.9 billion was met with some disappointment [7][8] - Supermicro's Q1 revenue fell to $5.02 billion, below analyst expectations, marking the sixth consecutive quarter of underperformance [8] - Pinterest's Q3 revenue was $1.05 billion, meeting expectations, but the Q4 guidance of $1.31 to $1.34 billion was below analyst forecasts, leading to an 18% pre-market drop [9] - Toyota's Q2 operating profit declined by 27% year-over-year, but the company raised its full-year profit and sales guidance [10] - Novo Nordisk's Q3 sales increased by 11% year-over-year, but operating profit fell by 21% [11] - Rivian's Q3 revenue reached $1.56 billion, a 78% increase year-over-year, with a positive gross margin reported [12] - Arista Networks reported Q3 revenue of $2.31 billion, a 27% increase, and provided a positive outlook for Q4 [13] - Astera Labs saw a 104% year-over-year revenue increase in Q3, but its Q4 earnings guidance fell short of expectations [14] - Tempus AI's Q3 revenue grew by 84.7%, but net losses widened [15] - McDonald's Q3 same-store sales grew by 3.6%, exceeding expectations, although EPS fell short [16] Upcoming Events - Key economic data releases include the U.S. ADP employment change and ISM non-manufacturing PMI scheduled for later today [16]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Insights - Tempus AI Inc. shares experienced a decline of 6.02% to $79.40 in after-hours trading following the release of its third-quarter earnings report [1] Financial Performance - Tempus AI reported third-quarter revenue of $334.21 million, exceeding analyst expectations of $328.73 million, and reflecting an 84.7% increase year-over-year [2] - The adjusted loss per share was 11 cents, better than the estimated loss of 17 cents, and a significant improvement from a loss of $21.8 million in the previous year. Adjusted EBITDA turned positive at $1.5 million [3] Future Guidance - For fiscal 2025, Tempus raised its full-year revenue forecast to $1.265 billion, indicating an expected growth of 80%, and anticipates slightly positive adjusted EBITDA [4] Stock Performance - Year-to-date, Tempus AI shares have increased by 146.69%, although they have decreased by 9.23% over the past month. The stock has a 52-week range of $31.36 to $104.32 and a market capitalization of $14.68 billion [5]

Core Insights - Tempus AI reported a revenue of $334.21 million for the quarter ended September 2025, reflecting an 84.7% increase year-over-year and a 2.38% surprise over the Zacks Consensus Estimate of $326.43 million [1] - The company's EPS was -$0.11, an improvement from -$0.25 in the same quarter last year, with a surprise of +31.25% compared to the consensus estimate of -$0.16 [1] Revenue Breakdown - Net Revenue from Data and Services was $81.33 million, slightly below the average estimate of $81.6 million from five analysts [4] - Net Revenue from Genomics reached $252.88 million, exceeding the average estimate of $244.82 million from five analysts [4] Profitability Metrics - Non-GAAP Gross Profit from Genomics was reported at $155.9 million, surpassing the estimated $141.1 million from three analysts [4] - Non-GAAP Gross Profit from Data and Services was $56.66 million, falling short of the estimated $60.07 million from three analysts [4] Stock Performance - Over the past month, Tempus shares have returned -4.7%, contrasting with the Zacks S&P 500 composite's +2.1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Tempus AI reported Q3 2025 revenue of $334.2 million, a significant increase of 84.7% year-over-year, surpassing market expectations of $328.73 million [1] - The company experienced a net loss of $80 million in Q3, which is wider than the $75.8 million loss in the same period last year, influenced by one-time expenses [1] - The adjusted EBITDA for Q3 was $1.5 million, a recovery from a loss of $21.8 million in the previous year [2] Revenue Breakdown - Genomics revenue reached $252.9 million, up 117.2% year-over-year, with tumor testing contributing $139.5 million, a 31.7% increase [2] - Genetic testing revenue from Ambry Genetics was $102.6 million, reflecting a 32.8% increase, while data and services revenue grew by 26.1% to $81.3 million [2] - The gross profit for Q3 was $209.9 million, marking a 98.4% increase compared to the previous year [2] Operational Highlights - The company acquired digital pathology AI firm Paige to enhance its data set and technical team [3] - Tempus AI was selected by ARPA-H for the ADAPT program to provide testing and CRO services [3] - The company received FDA 510(k) clearance for several products, including xR IVD and Tempus Pixel cardiac imaging platform [3] Future Outlook - Tempus AI raised its full-year 2025 revenue guidance to approximately $1.265 billion, representing an expected growth of about 80% [3] - The company anticipates an adjusted EBITDA of approximately $20 million for Q4, with a slight positive adjusted EBITDA for the full year [3] Financial Position - As of the end of the quarter, Tempus AI held $764.3 million in cash and securities [4]

Market Overview - US stock markets experienced a significant decline, with the Nasdaq falling over 2.5% and the semiconductor index dropping 4% [1] - The Dow Jones Industrial Average closed down 251.44 points (0.53%) at 47085.24, the Nasdaq down 486.09 points (2.04%) at 23348.64, and the S&P 500 down 80.34 points (1.17%) at 6771.63 [1] - Major tech companies saw declines, with Microsoft down 0.52%, Meta down 1.63%, Amazon down 1.84%, Google down 2.18%, Nvidia down 3.96%, and Tesla down 5.15% [1] Oil and Currency Markets - Oil prices fell due to a strong dollar and oversupply expectations, with WTI crude oil down 0.8% to $60.56 per barrel and Brent crude down 0.7% to $64.44 per barrel [2] - The ICE dollar index rose 0.38%, reaching a high of 100.255 points, while the Bloomberg dollar index also increased by 0.38% to 1226.13 points [2] Cryptocurrency Market - Bitcoin fell below the $100,000 mark for the first time since June, dropping over 6.5% to $100,870, with a low of $99,966 during the day [5] - Ethereum also saw a significant decline, dropping nearly 10% to $3,296 [5] Macro Economic News - The US government shutdown has reached its sixth week, tying the record for the longest shutdown in history, with uncertainty surrounding the potential for political compromise following recent elections [4] - The Senate has repeatedly rejected temporary funding proposals from the House, with no change in stance from either party [4] Company Earnings and Forecasts - AMD reported a significant year-over-year revenue increase of 36% to $9.25 billion, exceeding Wall Street's expectations, but its fourth-quarter guidance did not impress investors [7] - Arista Networks reported strong Q3 results with revenue of $2.31 billion, up 27% year-over-year, and adjusted EPS of $0.75, surpassing market expectations [8] - Tempus AI reported Q3 revenue of $334.2 million, a year-over-year increase of 84.7%, but net losses widened due to various one-time expenses [9] Investment Sentiment - CEOs from Goldman Sachs and Morgan Stanley warned of potential market corrections, suggesting a 10% to 20% pullback in the next 12 to 24 months due to current valuation concerns [6] - Michael Burry's fund disclosed short positions in Nvidia and Palantir, indicating a bearish outlook on AI stocks amid concerns of an AI bubble [10]

Core Insights - Tempus AI reported a quarterly loss of $0.11 per share, better than the Zacks Consensus Estimate of a loss of $0.16, and improved from a loss of $0.25 per share a year ago, resulting in an earnings surprise of +31.25% [1] - The company achieved revenues of $334.21 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 2.38% and significantly up from $180.93 million in the same quarter last year [2] - Tempus shares have increased approximately 162.8% year-to-date, outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The future performance of Tempus stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $361.46 million, and for the current fiscal year, it is -$0.69 on revenues of $1.26 billion [7] Industry Context - The Medical Info Systems industry, to which Tempus belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The correlation between near-term stock movements and earnings estimate revisions suggests that tracking these revisions can provide insights into stock performance [5]

Financial Data and Key Metrics Changes - The company reported a strong overall growth of 33% in genomics volume, with oncology growing at 27% and hereditary testing at 37% [4] - Positive adjusted EBITDA was achieved for the first time, marking a significant milestone after 10 years of efforts [5] - The company expects to be slightly positive in adjusted EBITDA for the year, despite additional expenses from the Paige acquisition [5] Business Line Data and Key Metrics Changes - The data licensing or insights business grew by 38% in the quarter, contributing an additional $150 million in total contract value [4] - The genomic growth was broad-based, with all assays performing exceptionally well [4] Market Data and Key Metrics Changes - The company noted that testing volumes have been healthy as more biomarkers are identified, contributing to the overall growth in the genomics market [10] - The average reimbursement for the third quarter was $1,600, which is still below parity with peers [30] Company Strategy and Development Direction - The company aims for sustained long-term unit growth and revenue growth, targeting about 25% growth for the next three years [15] - The integration of digital pathology with genomic diagnostics is expected to enhance sequencing capabilities and improve patient outcomes [61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of the hereditary business, expecting it to grow in the low to mid-20s range [35] - The company is well-positioned to benefit from future reimbursement changes in the healthcare system, particularly for data interpretation and analysis [52] Other Important Information - The foundation model is progressing well, with expectations to enter the post-training phase later this year and have the first versions ready by Q1 2026 [46] - The company is actively investing in AI and cloud computing to enhance its technological capabilities [47] Q&A Session Summary Question: What is driving the strong growth in the oncology portfolio? - The growth is attributed to a more efficient sales force and the integration of technology that provides comprehensive results to physicians [9][10] Question: How is the company planning to market MRD testing? - The company plans to gradually increase market presence as reimbursement becomes available, leveraging a well-trained sales force [17] Question: Can you provide details on the $150 million in new contracts? - The company highlighted that these contracts are multi-year deals and do not directly translate to immediate revenue increases [21][22] Question: How does Ambry's growth compare to the broader market? - Ambry's growth is primarily driven by share gains, and the company expects its growth to moderate in Q4 [34] Question: What updates can you provide on the foundation model with AstraZeneca and Pathos? - The foundation model is in the pretraining phase, with positive progress and expectations for the first versions to be ready in early 2026 [46] Question: How does the company view the potential for reimbursement of data interpretation? - Management believes that reimbursement for data interpretation will eventually be necessary for scaling, positioning the company well for future growth [52]

Financial Data and Key Metrics Changes - In Q3 2025, the company reported a strong overall growth of 33% in genomics volume, with oncology growing at 27% and hereditary testing at 37% [5][6] - The company achieved positive Adjusted EBITDA for the first time, a key milestone after 10 years of efforts, despite incurring additional expenses from the Paige acquisition [7][8] - The company expects to be slightly positive in Adjusted EBITDA for the year, even with the additional expenses from Paige [8] Business Line Data and Key Metrics Changes - The data licensing or insights business grew by 38% in the quarter, contributing an additional $150 million in total contract value [6][7] - The genomic growth was broad-based, with all assays performing exceptionally well [5][6] Market Data and Key Metrics Changes - The company noted that the overall market for testing volumes has been healthy, driven by the identification of more biomarkers [14] - The company is positioned to benefit from a broader market shift towards more NGS testing, although it does not see any one-time benefits artificially propping up its growth [16] Company Strategy and Development Direction - The company aims for sustained long-term unit growth and revenue growth, targeting about 25% growth for the next three years [20][22] - The integration of digital pathology with genomic diagnostics is expected to enhance sequencing capabilities and improve patient outcomes [75][77] - The company is investing heavily in AI and technology to differentiate itself in the market, aiming to operate like a tech company [59][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of the hereditary business, expecting it to grow in the low to mid-20s, significantly above the industry average [44][46] - The company believes that the healthcare reimbursement system will eventually adapt to cover data interpretation and analysis, which could lead to rapid scaling of its algorithms [66][70] Other Important Information - The foundation model is progressing well, with expectations to enter the post-training phase by early 2026 [58][60] - The company is focused on maintaining a strong portfolio of both naive and informed products in the MRD space, leveraging its trained salesforce [22][21] Q&A Session Summary Question: What is driving the strong growth in the oncology portfolio? - The CEO attributed the growth to a more efficient salesforce and the integration of technology that provides comprehensive results to physicians [11][13] Question: How is the company planning to market MRD testing? - The CEO indicated that the company will gradually increase its market presence as reimbursement becomes available, aiming for sustainable growth rather than a sudden spike [20][22] Question: Can you provide details on the $150 million in new contracts? - The CEO explained that the company highlights significant deals when they bundle together, and these contracts are typically multi-year, not immediately translating to revenue [29][30] Question: How does the company view the competitive landscape in hereditary testing? - Management noted that Ambry's growth is driven by both share gains and organic expansion, expecting to outperform the broader market [44][46] Question: What updates can you provide on the foundation model with AstraZeneca? - The CEO reported that the foundation model is in the pretraining phase and is expected to enter post-training by early 2026, with promising progress [58][60] Question: How does the company plan to address reimbursement for data interpretation? - The CEO emphasized the need for the healthcare system to adapt to reimburse for data analysis, which could lead to significant revenue growth for the company [66][70]